Spot Urine Protein/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study

IF 2.7 4区 医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-01-13 DOI:10.1016/j.clml.2025.01.003
Saad Jamshed , Mohammad Ammad-Ud-Din , Kimberly Celotto , Irfan Ul Haq Minhas , Jonathan Bress , Jens Hillengass
{"title":"Spot Urine Protein/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study","authors":"Saad Jamshed ,&nbsp;Mohammad Ammad-Ud-Din ,&nbsp;Kimberly Celotto ,&nbsp;Irfan Ul Haq Minhas ,&nbsp;Jonathan Bress ,&nbsp;Jens Hillengass","doi":"10.1016/j.clml.2025.01.003","DOIUrl":null,"url":null,"abstract":"<div><div>Measurement of 24- hour urine protein electrophoresis (PEP) and immunofixation (IFE) are part of standard diagnostic evaluation and monitoring of patients with suspected and diagnosed monoclonal plasma cell disorder for baseline evaluation of renal dysfunction or nephrotic syndrome. Measurement of 24-hour urine protein can however be time consuming and cumbersome and many centers have moved towards random urine protein measurements. The evidence for correlation between spot urine protein creatinine ratio (SUPC) and 24-hour urine protein measurements its scarce. Therefore, we have carried out a prospective study with a sample size of 40 multiple myeloma (MM) patients to demonstrate this correlation. Our results suggest a good correlation between SUPC and 24-hour urine protein measurements, suggesting SUPC testing is a reliable and easier alternative to 24-hour urine collection. These findings should now be confirmed in larger patient populations including early stage plasma cell disorders, light chain amyloidosis and symptomatic MM.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 6","pages":"Pages 449-453"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S215226502500014X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Measurement of 24- hour urine protein electrophoresis (PEP) and immunofixation (IFE) are part of standard diagnostic evaluation and monitoring of patients with suspected and diagnosed monoclonal plasma cell disorder for baseline evaluation of renal dysfunction or nephrotic syndrome. Measurement of 24-hour urine protein can however be time consuming and cumbersome and many centers have moved towards random urine protein measurements. The evidence for correlation between spot urine protein creatinine ratio (SUPC) and 24-hour urine protein measurements its scarce. Therefore, we have carried out a prospective study with a sample size of 40 multiple myeloma (MM) patients to demonstrate this correlation. Our results suggest a good correlation between SUPC and 24-hour urine protein measurements, suggesting SUPC testing is a reliable and easier alternative to 24-hour urine collection. These findings should now be confirmed in larger patient populations including early stage plasma cell disorders, light chain amyloidosis and symptomatic MM.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
斑点尿蛋白/肌酐比值替代24小时尿液采集测量多发性骨髓瘤患者蛋白尿:一项前瞻性研究
24小时尿蛋白电泳(PEP)和免疫固定(IFE)测量是怀疑和诊断为单克隆浆细胞疾病的患者的标准诊断评估和监测的一部分,用于肾功能障碍或肾病综合征的基线评估。然而,24小时尿蛋白的测量既耗时又繁琐,许多中心已经转向随机尿蛋白测量。就地尿蛋白肌酐比值(SUPC)与24小时尿蛋白测量值之间的相关性尚缺乏证据。因此,我们进行了一项前瞻性研究,样本量为40例多发性骨髓瘤(MM)患者,以证明这种相关性。我们的研究结果表明SUPC与24小时尿液蛋白测量之间存在良好的相关性,表明SUPC检测是一种可靠且更容易的替代24小时尿液收集的方法。这些发现现在应该在更大的患者群体中得到证实,包括早期浆细胞疾病、轻链淀粉样变性和症状性MM。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
期刊最新文献
SOHO State of the Art Updates and Next Questions | The Promise of Immunotherapies in T-Cell Lymphoma. Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial. SOHO State of the Art Updates and Next Questions | Success of a Modified Adolescent and Young Adult Treatment for Acute Lymphoblastic Leukemia in Mexico. Prevalence and Prognostic Impact of NPM1 Mutation in Childhood Acute Myeloid Leukemia: Experience from a Single Tertiary Cancer Centre in India. Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1